Request Trial
15 December 2024NewsAmericasChristopher Sweeney Executive Director Acuitas Therapeutics, Alison Maddeford Director Litigation & Risk Management Thermo Fisher Scientific, Daniel Yarbrough Head of Intellectual Property Element Biosciences, Madhuri Roy Partner Cooley

WATCH: The challenge of protecting patents and innovation - obviousness-type double patenting post In re Cellect

Speakers from Acuitas Therapeutics, Thermo Fisher Scientific, Element Biosciences, and Cooley examine the risks and implications of obviousness-type double patenting and offer guidance for mitigating its impact on innovation.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
From the courtroom: Hikma v Amarin SCOTUS oral arguments
30 April 2026   The Supreme Court's first look at the skinny label dispute dug into key questions, from the role of the skinny label to who Hikma’s statements were really meant for, in one of the most important patent cases in years.
Americas
CureVac targets Moderna with 10-patent suit over Spikevax
28 April 2026   BioNTech’s former rival—now part of its company—is seeking to assert its mRNA portfolio against Moderna in a new suit over modifications to the highly fought-over molecule.
Americas
Amneal acquires biopharma ahead of $300bn patent wave
23 April 2026   The US pharma giant is spending up to $1 billion to build an end-to-end biosimilar platform and is counting on a decade of expiring biologic patents to make it pay off.


Editor's picks

From the courtroom: Hikma v Amarin SCOTUS oral arguments
Americas
From the courtroom: Hikma v Amarin SCOTUS oral arguments
30 April 2026

Editor's picks

Americas
From the courtroom: Hikma v Amarin SCOTUS oral arguments
30 April 2026
Biotechnology
Closing the women's health gap offers ‘benefits for all’
7 April 2026
Europe
European patent offices raise fees
2 April 2026
Americas
Argentina’s patent reset: Why pharma can no longer ignore Latin America's second-largest market
1 April 2026
Europe
WIPR debuts Global In-House Elite 2026
26 March 2026
Biotechnology
mRNA litigation: Who’s winning, who’s filing, and what’s next
25 March 2026

More features

Squire Patton Boggs promotes partner to head Europe IP&T practice
From the courtroom: Hikma v Amarin SCOTUS oral arguments
Report: 85% of in-house counsel want IP service providers to embrace AI
Moderna loses key mRNA patent in European vaccine fight
Boston-based patent expert departs Mintz for major West Coast firm
Blow for Masimo’s fight with Apple as case against US Customs dismissed
Ligand buys biotech in $739m cash deal with litigation sweetener
CureVac targets Moderna with 10-patent suit over Spikevax